Experienced in RUNX1 Familial Platelet Disorder

Dr. Hongtao Liu

Hematology | Oncology | Transplant Surgery
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
Accepting New Patients
Experienced in RUNX1 Familial Platelet Disorder
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hongtao Liu is a Hematologist and an Oncologist in Madison, Wisconsin. Dr. Liu is rated as an Experienced provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Liu is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Transplant Surgery
Licenses
Internal Medicine in WI
Hospital Affiliations
University Of Wi Hospitals & Clinics Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Associates
  • MEDICARE MAPD
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
600 Highland Ave, Madison, WI 53792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)
A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug, Device, Radiation
Study Drugs: Fludarabine, Melphalan, Anti-Thymocyte Globulin, Rituximab, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Biological
Study Drug: IO-202
Study Phase: Phase 1
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Biological
Study Drug: NKX019
Study Phase: Phase 1
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drug: Midostaurin
Study Phase: Phase 3
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation
Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: May 13, 2021
Intervention Type: Drug, Other
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)
Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)
Enrollment Status: Completed
Publish Date: April 08, 2020
Intervention Type: Drug
Study Phase: Phase 1
Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies
Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 07, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 17 Less Clinical Trials

118 Total Publications

Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis.
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis.
Journal: Blood advances
Published: February 11, 2025
Similar Doctors
Advanced in RUNX1 Familial Platelet Disorder
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology
Advanced in RUNX1 Familial Platelet Disorder
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology

University Of Wisconsin Medical Foundation Inc

1400 E Side Rd, 
Platteville, WI 
 (57.5 miles away)
608-348-2331
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rubina Qamar is a Hematologist Oncology specialist and an Oncologist in Platteville, Wisconsin. Dr. Qamar is rated as a Distinguished provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Tissue Biopsy. Dr. Qamar is currently accepting new patients.

Experienced in RUNX1 Familial Platelet Disorder
Dr. Jane E. Churpek
Hematology Oncology | Hematology | Oncology
Experienced in RUNX1 Familial Platelet Disorder
Dr. Jane E. Churpek
Hematology Oncology | Hematology | Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Churpek is a Hematologist Oncology specialist and a Hematologist in Madison, Wisconsin. Dr. Churpek is rated as an Advanced provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Li-Fraumeni Syndrome, Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Churpek is currently accepting new patients.

Experienced in RUNX1 Familial Platelet Disorder
Dr. Harvey E. Einhorn
Hematology Oncology | Hematology | Oncology
Experienced in RUNX1 Familial Platelet Disorder
Dr. Harvey E. Einhorn
Hematology Oncology | Hematology | Oncology

Swedishamerican Hospital

3505 N Bell School Rd, 
Rockford, IL 
 (57.9 miles away)
779-696-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harvey Einhorn is a Hematologist Oncology specialist and a Hematologist in Rockford, Illinois. Dr. Einhorn is rated as a Distinguished provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Einhorn is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liu's expertise for a condition
ConditionClose
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile